Insmed reports successful phase 3b trial for lung disease drug ARIKAYCE
Go back to Insmed reports successful phase 3b trial for lung disease drug ARIKAYCE| INSMED (NASDAQ: INSM) | Delayed: 99.17 +0.56 (0.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.61 | 52 Week High | $19.30 | |||
| Open | $98.84 | 52 Week Low | $9.02 | |||
| Day High | $101.16 | P/E | N/A | |||
| Day Low | $97.60 | EPS | $-1.69 | |||
| Volume | 721,621 | |||||
